The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: A pilot study

Journal of Physiology and Pharmacology

Volumn 63, Issue 1, 2012, Pages 35-40

  Gonciarz, M ^a   Gonciarz, Z ^b   Bielanski, W ^c   Mularczyk, A ^a   Konturek, P C ^d   Brzozowski, T ^c   Konturek, S J ^c  

^a St Barbara's Main District Hospital   (Poland)

^b Silesian School of Management   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d Thuringia Clinic Saalfeld   (Germany)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Lipids; Liver enzymes; Melatonin; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; LIPID; LIVER ENZYME; MELATONIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; LONG TERM CARE; MALE; NONALCOHOLIC FATTY LIVER; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CHOLESTEROL; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIPIDS; LIVER; MALE; MELATONIN; PILOT PROJECTS; TRIGLYCERIDES;

EID: 84859127888     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161.
2. Starley B, Calcagno Ch, Harrison S. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weight connection. Hepatology 2010; 51: 1820-1832.
3. Ong J, Younoshi Z. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16
4. Ascha M, Hanouneh I, Lopez R, Tamimi T, Feldstein A, Zein N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
5. Duvnjak L, Duvniak M. The metabolic syndrome-an ongoing story. J Physiol Pharmacol 2009; 60(Suppl. 7): 19-24.
6. Arendt B, Allard J. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease is the combination required? Am J Gastroenterol 2011; 106: 78-80.
7. Pagadala M, Zein C, McCullough J. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2009; 13: 591-606.
8. Larter C, Chitturi S, Heydel D, Farrell G. A Fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25: 672-690.
9. Dowman J, Tomlinson J, Newsome P. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83.
10. Duvnjak M, Tomasic V, Gomericic M, Smircic-Duvnjak L, Barsic N, Lerotic I. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009; 60(Suppl.7): 57-66.
11. Targher G, Bellis A, Fornego P, et al. Prevention and treatment of nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42: 331-340.
12. Sanyal A, Chalsani N, Koudley K, et al. Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis. NEJM 2010; 362: 1675-1685.
13. Gonciarz M, Gonciarz Z, Bielanski W, et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol 2010; 61: 705-710.
14. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-128.
15. Pomrat K, Kleiner D, Niemeier H, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129.
16. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol 2011; 26(Suppl.1): 173-179.
17. Ono M, Okamoto N, Saibara T. The latest idea in NAFLD/NASH pathogenesis. Clin J Gastroenterol 2010; 3: 263-270.
18. Foster T, Budoff M, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis heart study randomized clinical trial. Am J Gastroenterol 2011; 106: 71-77.
19. Dufour J. Vitamin E for nonalcoholic steatohepatitis: ready for prime time? Hepatology 2010; 52: 789-792.
20. Konturek S, Konturek P, Brzozowski T, et al. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol 2007; 58: 381-405.
21. Majewska M, Zajac K, Zemelka M, Szczepanik M. Influence of melatonin and its precursor L-trptophan on TH1 dependent contact hypersensivity. J Physiol Pharmacol 2007; 58(Suppl. 6): 125-132.
22. Paradies G, Petrosilo G, Paradies V, Reiter R, Ruggiero F. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
23. Galano A, Tan D, Reiter R. Melatonin as a natural ally against oxidative stress: a physiochemical examination. J Pineal Res 2011; 51: 1-16.
24. Jun-Hua L, Jie-Ping Y, Hong-Gang Y, et al. Melatonin reduces inflammatory injury through inhibiting NF-κB activation in rats with colitis. Mediators Inflamm 2005; 4: 185-193.
25. Aranda M, Albendea C, Lostale F, et al. In vivo hepatic oxidative stress because of carbon tetrachloride toxicity: protection by melatonin and pinoline. J Pineal Res 2010; 49: 78-85.
26. Rios-Lugo M, Cano P, Jimenez-Ortega V, et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerydes and cholesterol in normal and high fat-fed rats. J Pineal Res 2010; 49: 342-348.
27. Akcan A, Kucuk C, Sozuer E, et al. Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J Gastroenterol 2008; 14: 918-924.
28. Zaouali M, Reiter R, Pardissa-Altes S, et al. Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. J Pineal Res 2011; 50: 213-221.
29. Saha L, Malhorta S, Rana S, et al. A preliminary stydy of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007; 41: 29-32.
30. Kozirog M, Poliwczak A, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011; 50: 389-394.
31. Celinski K, Konturek SJ, Konturek P, et al. Melatonin or tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res 2011; 50: 261-266.
32. Cichoz-Lach H, Celinski K, Konturek PC, Konturek SJ, Slomka M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatophepatitis. J Physiol Pharmacol 2010; 61: 577-580.
33. Chahbouni M, Escames G, Venegas C, et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010; 48: 282-289.